Ensysce Biosciences, Inc.ENSCNASDAQ
Loading
Operating Income Growth Under PressureDecelerating
Percentile Rank25
Year-over-Year Change
Year-over-year operating income growth rate
Percentile
P25
Within normal range
vs 3Y Ago
-9x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -113.71% |
| Q2 2025 | 11.05% |
| Q1 2025 | 44.97% |
| Q4 2024 | -654.71% |
| Q3 2024 | 132.97% |
| Q2 2024 | -6.10% |
| Q1 2024 | 41.60% |
| Q4 2023 | -16.56% |
| Q3 2023 | -18.02% |
| Q2 2023 | 10.44% |
| Q1 2023 | 58.69% |
| Q4 2022 | -0.61% |
| Q3 2022 | 12.64% |
| Q2 2022 | -46.89% |
| Q1 2022 | -139.33% |
| Q4 2021 | 88.12% |
| Q3 2021 | -3992.61% |
| Q2 2021 | 21.30% |
| Q1 2021 | 52.05% |
| Q4 2020 | -170.11% |
| Q3 2020 | -391.03% |
| Q2 2020 | 154.70% |
| Q1 2020 | 86.82% |
| Q4 2019 | -230.33% |
| Q3 2019 | 6.71% |
| Q2 2019 | -231.22% |
| Q1 2019 | 76.55% |
| Q4 2018 | -225.00% |
| Q3 2018 | 20.51% |
| Q2 2018 | -83.53% |
| Q1 2018 | -19.72% |
| Q4 2017 | 0.00% |
| Q3 2017 | 0.00% |